ceftriaxone IM
Selected indexed studies
- The 2024 European guideline on the management of epididymo-orchitis. (J Eur Acad Dermatol Venereol, 2026) [PMID:40698982]
- [Whipple's disease]. (Praxis (Bern 1994), 2007) [PMID:17256556]
- Ceftriaxone use for acute otitis media: Associated factors in a large U.S. primary care population. (Int J Pediatr Otorhinolaryngol, 2022) [PMID:35841649]
_Worker-drafted node — pending editorial review._
Connections
ceftriaxone IM is a side effect of
Sources
- Ceftriaxone use for acute otitis media: Associated factors in a large U.S. primary care population. (2022) pubmed
- The 2024 European guideline on the management of epididymo-orchitis. (2026) pubmed
- [Whipple's disease]. (2007) pubmed
- Ceftriaxone-induced immune hemolytic anemia. (2014) pubmed
- Predicting the limit to ceftriaxone's use in gonorrhea treatment: impending resistance and logistical challenges. (2025) pubmed
- Pelvic inflammatory diseases: Updated French guidelines. (2020) pubmed
- Lyme myositis. (2006) pubmed
- Ceftriaxone pharmacokinetics following multiple intramuscular dosing. (1986) pubmed
- Pulmonary Embolism After Ceftriaxone-Induced Anaphylaxis. (2017) pubmed
- Pharmacokinetics and safety of ceftriaxone in the neonate. (1985) pubmed